[What is safe in the therapy of advanced prostatic cancer?].
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002064:Buserelin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D045166:Estradiol Congeners / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D045166:Estradiol Congeners; D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D016729:Leuprolide; D002064:Buserelin
Was ist gesichert in der Therapie des fortgeschrittenen Prostatacarcinoms?